Stocks and Investing
Stocks and Investing
Fri, December 4, 2020
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Thu, December 3, 2020
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Konstantinos Aprilakis Initiated (SNDX) at Strong Buy and Held Target at $32 on, Dec 3rd, 2020
Konstantinos Aprilakis of Stifel, Initiated "Syndax Pharmaceuticals, Inc." (SNDX) at Strong Buy and Held Target at $32 on, Dec 3rd, 2020.
Konstantinos has made no other calls on SNDX in the last 4 months.
There is 1 other peer that has a rating on SNDX. Out of the 1 peers that are also analyzing SNDX, all agrees with Konstantinos's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- David Lebowitz of "Morgan Stanley" Maintained at Hold with Increased Target to $17 on, Wednesday, November 4th, 2020
Contributing Sources